약독화 생백신 시장 보고서(2026년)

Live attenuated vaccines are biological formulations that contain a weakened form of a virus or bacterium, engineered in the lab to prevent it from causing illness in healthy individuals. By closely mimicking a natural infection, these vaccines elicit a strong and long-lasting immune response, often requiring only one or two doses for effective protection against infectious diseases.

The main types of live attenuated vaccines include monovalent and multivalent vaccines. Monovalent vaccines target a single specific antigen, strain, or type. They are administered via intramuscular, subcutaneous, oral, or intranasal routes for various indications, including influenza, measles, mumps, rubella (MMR), polio, chickenpox, shingles, rotavirus, and others. These vaccines are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, clinics, diagnostic centers, research institutes, and other healthcare providers.

Tariffs have influenced the live attenuated vaccines market by increasing expenses related to viral seed strains, bioreactor consumables, cold-chain packaging, and international vaccine transport. Pediatric immunization programs and mass vaccination campaigns are most affected, particularly in Asia-Pacific and North America where cross-border vaccine supply chains are common. Hospitals, clinics, and public health distributors experience higher vaccine procurement costs. However, tariffs are accelerating domestic vaccine production and regional fill-and-finish capabilities, improving national vaccine security.

The live attenuated vaccines market research report is one of a series of new reports from The Business Research Company that provides live attenuated vaccines market statistics, including live attenuated vaccines industry global market size, regional shares, competitors with a live attenuated vaccines market share, detailed live attenuated vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated vaccines industry. This live attenuated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The live attenuated vaccines market size has grown strongly in recent years. It will grow from $25.95 billion in 2025 to $28.52 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, WHO vaccination programs.

The live attenuated vaccines market size is expected to see strong growth in the next few years. It will grow to $41.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to booster vaccination demand, emerging infectious disease risks, cold chain infrastructure expansion, global health funding, next-generation vaccine platforms. Major trends in the forecast period include expansion of national immunization programs, growing demand for pediatric vaccination, advances in vaccine stability and storage, increased focus on pandemic preparedness, multivalent vaccine development.

The increasing prevalence of infectious diseases is expected to drive growth in the live attenuated vaccines market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, which can spread directly or indirectly between people, animals, or the environment. Rising global travel accelerates the spread of these diseases by enabling pathogens to cross borders faster than containment efforts can respond. Live attenuated vaccines prevent infectious diseases by stimulating a strong immune response using weakened pathogens, ensuring long-term immunity and reducing transmission. For example, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 10.8 million people worldwide contracted tuberculosis in 2023, including 6.0 million men, 3.6 million women, and 1.3 million children. Therefore, the rising prevalence of infectious diseases is driving growth in the live attenuated vaccines market.

Major companies in the live attenuated vaccines market are focusing on advanced products, such as single-dose vaccines, to enhance immunization efficiency and improve patient compliance. Single-dose vaccines provide lasting immunity with just one shot, eliminating the need for multiple doses and simplifying vaccination for both patients and healthcare providers. For instance, in November 2023, Valneva SE, a France-based biotech company, launched IXCHIQ, which received approval from the U.S. Food and Drug Administration (FDA). IXCHIQ is the world's first live-attenuated chikungunya vaccine for adults aged 18 and older, addressing an unmet need for protection against this mosquito-borne viral disease that can cause severe fever, joint and muscle pain, and other symptoms.

In May 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired a travel health business from Emergent BioSolutions Inc. for approximately $380 million. This acquisition expanded Bavarian Nordic's vaccine portfolio to include VIVOTIF for typhoid fever, VAXCHORA for cholera, and the chikungunya vaccine candidate CHIKV VLP, along with associated manufacturing and development facilities in Switzerland and California. Emergent BioSolutions Inc., based in the U.S., specializes in manufacturing live attenuated vaccines.

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the live attenuated vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The live attenuated vaccine market consists of sales of viral live attenuated vaccines, bacterial live attenuated vaccines, and intranasal live attenuated vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Live Attenuated Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses live attenuated vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for live attenuated vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The live attenuated vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Vaccine Type: Monovalent; Multivalent
• 2) By Route Of Administration: Intramuscular; Subcutaneous; Oral Attenuated; Intranasal Attenuated
• 3) By Indication: Influenza; Measles, Mumps and Rubella (MMR); Polio; Chickenpox; Shingles; Rotavirus; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Clinics; Diagnostic Centers; Research Institute; Other End-Users
• Subsegments:
• 1) By Monovalent: Single-Dose Vaccines; Multiple-Dose Vaccines
• 2) By Multivalent: Bivalent Vaccines; Trivalent Vaccines; Quadrivalent Vaccines; Other Multivalent Vaccines
• Companies Mentioned: Merck & Co. Inc.; Sanofi SA; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Boehringer Ingelheim International GmbH; CSL Limited; GC Biopharma; Serum Institute of India Pvt. Ltd.; Bavarian Nordic; Valneva SE; Southern Research; BioFarma; Bharat Biotech International Limited; Meissa Vaccines Inc.; BioDiem Ltd.; Bio-Med Limited; Naobios; Lakshmi Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Live Attenuated Vaccines Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Live Attenuated Vaccines Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Live Attenuated Vaccines Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Live Attenuated Vaccines Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Industry 4.0 & Intelligent Manufacturing
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Expansion Of National Immunization Programs
  • 4.2.2 Growing Demand For Pediatric Vaccination
  • 4.2.3 Advances In Vaccine Stability And Storage
  • 4.2.4 Increased Focus On Pandemic Preparedness
  • 4.2.5 Multivalent Vaccine Development

5. Live Attenuated Vaccines Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Public Health Centers
• 5.4 Immunization Centers
• 5.5 Research Institutes

6. Live Attenuated Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Live Attenuated Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Live Attenuated Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Live Attenuated Vaccines Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Live Attenuated Vaccines Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Live Attenuated Vaccines Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Live Attenuated Vaccines Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Live Attenuated Vaccines Market Segmentation

• 9.1. Global Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monovalent, Multivalent
• 9.2. Global Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated
• 9.3. Global Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications
• 9.4. Global Live Attenuated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
• 9.5. Global Live Attenuated Vaccines Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users
• 9.6. Global Live Attenuated Vaccines Market, Sub-Segmentation Of Monovalent, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single-Dose Vaccines, Multiple-Dose Vaccines
• 9.7. Global Live Attenuated Vaccines Market, Sub-Segmentation Of Multivalent, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

10. Live Attenuated Vaccines Market Regional And Country Analysis

• 10.1. Global Live Attenuated Vaccines Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Live Attenuated Vaccines Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Live Attenuated Vaccines Market

• 11.1. Asia-Pacific Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Live Attenuated Vaccines Market

• 12.1. China Live Attenuated Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Live Attenuated Vaccines Market

• 13.1. India Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Live Attenuated Vaccines Market

• 14.1. Japan Live Attenuated Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Live Attenuated Vaccines Market

• 15.1. Australia Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Live Attenuated Vaccines Market

• 16.1. Indonesia Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Live Attenuated Vaccines Market

• 17.1. South Korea Live Attenuated Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Live Attenuated Vaccines Market

• 18.1. Taiwan Live Attenuated Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Live Attenuated Vaccines Market

• 19.1. South East Asia Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Live Attenuated Vaccines Market

• 20.1. Western Europe Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Live Attenuated Vaccines Market

• 21.1. UK Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Live Attenuated Vaccines Market

• 22.1. Germany Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Live Attenuated Vaccines Market

• 23.1. France Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Live Attenuated Vaccines Market

• 24.1. Italy Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Live Attenuated Vaccines Market

• 25.1. Spain Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Live Attenuated Vaccines Market

• 26.1. Eastern Europe Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Live Attenuated Vaccines Market

• 27.1. Russia Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Live Attenuated Vaccines Market

• 28.1. North America Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Live Attenuated Vaccines Market

• 29.1. USA Live Attenuated Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Live Attenuated Vaccines Market

• 30.1. Canada Live Attenuated Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Live Attenuated Vaccines Market

• 31.1. South America Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Live Attenuated Vaccines Market

• 32.1. Brazil Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Live Attenuated Vaccines Market

• 33.1. Middle East Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Live Attenuated Vaccines Market

• 34.1. Africa Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Live Attenuated Vaccines Market, Segmentation By Vaccine Type, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Live Attenuated Vaccines Market Regulatory and Investment Landscape

36. Live Attenuated Vaccines Market Competitive Landscape And Company Profiles

• 36.1. Live Attenuated Vaccines Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Live Attenuated Vaccines Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Live Attenuated Vaccines Market Company Profiles
  • 36.3.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. Live Attenuated Vaccines Market Other Major And Innovative Companies

• Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

38. Global Live Attenuated Vaccines Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Live Attenuated Vaccines Market

40. Live Attenuated Vaccines Market High Potential Countries, Segments and Strategies

• 40.1 Live Attenuated Vaccines Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Live Attenuated Vaccines Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Live Attenuated Vaccines Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer